

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

VOLUNTARY ANNOUNCEMENT
c-MetADC (RC108) OBTAINED INVESTIGATIONAL NEW DRUG
(IND) APPROVAL FROM NMPA FOR c-Met POSITIVE
ADVANCED SOLID TUMOR IN CHINA

This announcement is made by RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that RC108, the c-Met antibody drug conjugate (“**ADC**”) independently developed in-house by the Company, has recently obtained approval from China National Medical Products Administration (NMPA) to advance to phase I clinical trial for c-Met positive advanced solid tumors in China. RC108 is our third ADC products developed in-house that have entered into clinical development stage.

There has been a lot of significant progress made in the global ADC market in recent years, with a number of ADC products having shown promising developments in several types of solid tumors. RC108 is another significant development we have made after RC48 (Disitamab Vedotin) and RC88 as the Company continues to invest in and build a promising ADC product pipeline.

ABOUT RC108

RC108 is our third in-house developed ADC product that has entered clinical development stage. It is a c-Met-targeted ADC. c-Met is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in proliferation, motility, migration and invasion. It is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. We are developing RC108 as a monotherapy for the treatment of advanced solid tumors. We maintain the global rights to develop and commercialize RC108.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the c-MetADC (RC108) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
RemeGen Co., Ltd.
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
November 19, 2020

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Lorne Alan Babiuk as the independent non-executive directors.

* *For identification purposes only*